Your DNA may determine how well Weight-Loss drugs work

NCT ID NCT07653412

Recruiting now Knowledge-focused Sponsor: National and Kapodistrian University of Athens Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study looks at whether a person's genetic makeup can predict how much weight they will lose on the drugs semaglutide or tirzepatide. Researchers will follow 220 adults with obesity who are starting one of these medications for six months. By analyzing genetic risk scores and specific gene variants, the goal is to see if certain genetic profiles are linked to better or worse weight loss, which could one day help doctors tailor obesity treatment to each individual.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Semaglutide or Tirzepatide
What this could lead to: If successful, this could help doctors choose the most effective weight-loss drug for each person based on their genes, making treatment more personalized.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. The genetic score may not reliably predict response in all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTI-OBESITY AGENTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Genetic Risk Score Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTI-OBESITY AGENTS OBESITY (DISORDER) PRECISION MEDICINE

Contacts and locations

Locations

Laiko General Hospital, Athens
RECRUITING

Athens, 11527, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.